Tucson, Arizona 85712

  • Hepatitis C, Chronic


This single arm study will evaluate the efficacy and safety of PEGASYS (180 micrograms sc weekly) plus ribavirin (1000-1200mg po daily) in treatment-naive Latino patients versus non-Latino Caucasian patients with chronic hepatitis C- genotype 1. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ patients.


Inclusion Criteria: - adult patients 18-65 years of age - CHC, genotype 1 - serologic evidence of CHC infection by an antibody test - chronic liver disease, consistent with CHC infection on a liver biopsy obtained within the past 18 months - compensated liver disease - use of 2 forms of contraception during the study in both men and women Exclusion Criteria: - previous interferon or ribavirin therapy - systemic antiviral therapy less than 24 weeks before first dose of study drug or expected need for this treatment any time during the study - medical condition associated with chronic liver disease (eg, hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure) - decompensated liver disease - women who are pregnant or breastfeeding

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype

Official Title:

An Open-label Study of PEGASYS Plus Ribavirin on Sustained Virological Response in Treatment-naïve Latino White Patients Compared With Non-Latino Caucasian Patients With Chronic Hepatitis C, Genotype 1

Overall Status:


Study Phase:

Phase 4



Minimum Age:

18 Years

Maximum Age:

65 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Hoffmann-La Roche

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification: S

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Clinical Trials
Study Director
Hoffmann-La Roche

Study Dates

Start Date:August 2004
Completion Date:February 2008
Completion Type:Actual
Primary Completion Date:September 2007
Primary Completion Type:Actual
Verification Date:December 2015
Last Changed Date:December 1, 2015
First Received Date:April 6, 2005

Study Outcomes

Outcome Type:Secondary Outcome
Measure:AEs, laboratory parameters, premature withdrawals
Time Frame:Throughout study
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Percentage of patients with virologic response
Time Frame:Weeks 4, 12, 24, 48 and 12 and 24 weeks post-treatment
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Percentage of patients with early virologic response
Time Frame:Weeks 4 and 12
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Percentage of patients with sustained virologic response
Time Frame:24 weeks post-treatment
Safety Issues:False

Study Interventions

Intervention Type:Drug
Description:1000-1200mg po daily for 48 weeks
Arm Name:1
Intervention Type:Drug
Name:peginterferon alfa-2a [Pegasys]
Description:180 micrograms sc/week for 48 weeks
Arm Name:1

Study Arms

Study Arm Type:Experimental
Arm Name:1

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Hoffmann-La Roche

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.